Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

June 16th 2025

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

June 16th 2025

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.

ASCO 2025 Showcases Emerging Data on MRD-Guided Therapy, Trispecific Antibodies, and Frontline Bispecifics in Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma

June 15th 2025

Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.

Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression

June 15th 2025

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

June 14th 2025

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma

June 14th 2025

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

Talquetamab/Cetrelimab Leads to Deep, Durable Responses in R/R Multiple Myeloma

June 14th 2025

Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.

Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma

June 4th 2025

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma

June 4th 2025

ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma

June 3rd 2025

Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.

One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel

June 3rd 2025

A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.

Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma

June 3rd 2025

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.

SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

June 3rd 2025

Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.

D-VRd Retains Its Role as a Potential Standard of Care for Transplant-Ineligible Multiple Myeloma

June 2nd 2025

D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.

Belantamab Mafodotin Triplet Improves PFS, Responses in R/R Myeloma With High-Risk Cytogenetics

June 2nd 2025

Belantamab mafodotin plus Pd improved PFS and response rates in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

Talquetamab Is Safe and Effective in R/R Multiple Myeloma

June 1st 2025

Talquetamab led to durable responses and promising survival outcomes in patients with relapsed/refractory multiple myeloma.

Cilta-Cel Boosts Survival Vs SOC Across Key Subgroups of R/R Multiple Myeloma

June 1st 2025

CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.

Dr Richardson on Optimal Treatment Strategies for 1q–Amplified Multiple Myeloma

May 30th 2025

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Dr Dholaria on the Mechanism of Action of P-BCMA-ALLO1 in Multiple Myeloma

May 30th 2025

Bhagirathbhai Dholaria, MBBS, discusses the mechanism of action of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.